Phathom Pharmaceuticals, Inc.
NASDAQ:PHATBiotechnology
-$0.27 today
- Market cap
- $430.84M
- Beta
- 0.51
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.92
Volume 1.67M
Average 1.21M
Returns on capital
Phathom Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
50.5%
avg 58.2%
ROIC
-125.2%
avg -92.3%
ROA
-85.4%
avg -85.8%
Analysis
ROE is currently the strongest return metric at 50.5% versus its period average of 58.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David A. Socks | Co-Founder | USD 1.95M | 51 | 17.50K | 0.02% |
Azmi Nabulsi | Co-Founder | USD 1.95M | 66 | 55.00K | 0.07% |
Steven L. Basta | Chief Executive Officer, President & Director | USD 1.17M | 60 | 373.31K | 0.47% |
Anne Marie Cook | Chief Legal Officer & Corporate Secretary | USD 663.41K | 64 | 88.66K | 0.11% |
Sanjeev Narula | Chief Financial & Business Officer | USD 644.29K | 65 | 214.72K | 0.27% |
Robert Breedlove | Vice President of Finance & Principal Accounting Officer | — | — | — | — |
Nancy R. Phelan | Senior Vice President of Marketing & Analytics | — | 57 | — | — |
Bill Aprea | Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer | — | — | — | — |
Eric Sciorilli | Director of Business Development & Investor Relations | — | — | — | — |
Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | — | — | — | — |
Paul Cocja | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +40.1% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +40.1% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Phathom Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PHAT's management, answered from reported figures.
Who manages PHAT?
Phathom Pharmaceuticals, Inc. (PHAT) lists 11 active executives. The top listed executive is David A. Socks, Co-Founder.
Are PHAT insiders buying or selling?
Recent insider activity shows net selling of $30.69M.
Continue the stock analysis
Jump to another research area for this company.